<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:46:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7450289" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7450289</identifier>
        <datestamp>2020-09-11</datestamp>
        <setSpec>ict</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="publisher-id">ICT</journal-id>
              <journal-id journal-id-type="hwp">spict</journal-id>
              <journal-title-group>
                <journal-title>Integrative Cancer Therapies</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1534-7354</issn>
              <issn pub-type="epub">1552-695X</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7450289</article-id>
              <article-id pub-id-type="pmcid">PMC7450289</article-id>
              <article-id pub-id-type="pmc-uid">7450289</article-id>
              <article-id pub-id-type="pmid">32840126</article-id>
              <article-id pub-id-type="pmid">32840126</article-id>
              <article-id pub-id-type="doi">10.1177/1534735420944491</article-id>
              <article-id pub-id-type="publisher-id">10.1177_1534735420944491</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Preliminary Efficacy and Safety of Reishi &amp; Privet Formula on
Quality of Life Among Non–Small Cell Lung Cancer Patients Undergoing
Chemotherapy: A Randomized Placebo-Controlled Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6112-2947</contrib-id>
                  <name>
                    <surname>Liu</surname>
                    <given-names>Jie</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735420944491">1</xref>
                  <xref ref-type="aff" rid="aff2-1534735420944491">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mao</surname>
                    <given-names>Jun J.</given-names>
                  </name>
                  <degrees>MD, MSCE</degrees>
                  <xref ref-type="aff" rid="aff1-1534735420944491">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Susan Qing</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="aff1-1534735420944491">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lin</surname>
                    <given-names>Hongsheng</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff2-1534735420944491">2</xref>
                  <xref ref-type="corresp" rid="corresp1-1534735420944491"/>
                </contrib>
              </contrib-group>
              <aff id="aff1-1534735420944491"><label>1</label>Memorial Sloan Kettering Cancer Center,
New York, NY, USA</aff>
              <aff id="aff2-1534735420944491"><label>2</label>Guang An Men Hospital, Beijing,
China</aff>
              <author-notes>
                <corresp id="corresp1-1534735420944491">Hongsheng Lin, China Academy of Chinese
Medical Sciences (CACMS), Guang An Men Hospital, No. 5 Bei Xian Ge Street, Xi
Cheng District, Beijing 100053, China. Email:
<email>drlinhongsheng@163.com</email></corresp>
                <corresp id="corresp2-1534735420944491">Jie Liu, China Academy of Chinese Medical
Sciences (CACMS), Guang An Men Hospital, No. 5 Bei Xian Ge Street, Xi Cheng
District, Beijing 100053, China. Email:
<email>dr.liujie@163.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>19</volume>
              <elocation-id>1534735420944491</elocation-id>
              <history>
                <date date-type="received">
                  <day>13</day>
                  <month>12</month>
                  <year>2019</year>
                </date>
                <date date-type="rev-recd">
                  <day>26</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>3</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2020</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
                <license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
                  <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <sec id="section1-1534735420944491">
                  <title>Background:</title>
                  <p>Cancer patients often experience decreased quality of life during
chemotherapy. This study aimed to determine the preliminary efficacy and
safety of Reishi &amp; Privet Formula (RPF) for maintaining quality of life
among patients with non–small cell lung cancer (NSCLC) undergoing
chemotherapy.</p>
                </sec>
                <sec id="section2-1534735420944491">
                  <title>Methods:</title>
                  <p>We conducted a phase II randomized, double-blind, placebo-controlled clinical
trial in China. Adults with NSCLC scheduled to receive chemotherapy were
randomly assigned (3:1 ratio) to receive oral RPF (3.36 g/day) or placebo
daily for 6 weeks. The main outcome was the Functional Assessment of Cancer
Therapy–Lung (FACT-L). We evaluated RPF’s safety profile using the Common
Terminology Criteria for Adverse Events and assessed changes in outcome
measures from baseline to weeks 3 and 6 using a linear mixed effects
model.</p>
                </sec>
                <sec id="section3-1534735420944491">
                  <title>Results:</title>
                  <p>We enrolled 82 participants across 8 cancer centers in China. The median age
was 59 years, 56 (68%) had advanced cancer. Compared with the placebo group,
the RPF group had nonstatistically significant higher quality of life as
measured by the FACT-L total score (<italic>P</italic> = .086) over 2 cycles
of chemotherapy. The RPF group was associated with a nonsignificant better
general health (<italic>P</italic> = .050) and emotional well-being
(<italic>P</italic> = .090) than the placebo group. Adverse events rates
did not differ between groups.</p>
                </sec>
                <sec id="section4-1534735420944491">
                  <title>Conclusions:</title>
                  <p>This study demonstrated preliminary safety and suggests a promising trend in
RPF’s effect on maintaining quality of life and emotional well-being among
NSCLC patients undergoing chemotherapy. Future adequately powered
randomized-controlled trials are needed to verify the efficacy and safety of
RPF in cancer patients undergoing chemotherapy.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Reishi &amp; Privet formula</kwd>
                <kwd>traditional Chinese medicine</kwd>
                <kwd>herbs</kwd>
                <kwd>quality of life</kwd>
                <kwd>non–small cell lung cancer</kwd>
                <kwd>chemotherapy</kwd>
                <kwd>randomized placebo-controlled trial</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="award1-1534735420944491">
                  <funding-source id="funding1-1534735420944491">
                    <institution-wrap>
                      <institution>Nanjing Zhongke Pharmaceutical Co., Ltd</institution>
                      <institution-id/>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January-December 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="section5-1534735420944491">
              <title>Background</title>
              <p>Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer
deaths worldwide.<sup><xref rid="bibr1-1534735420944491" ref-type="bibr">1</xref></sup> Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all new
lung cancer cases. The average 5-year survival rate of NSCLC is no more than 23%.<sup><xref rid="bibr2-1534735420944491" ref-type="bibr">2</xref></sup> Patients often present at an advanced stage with a dismal prognosis (6%
5-year survival rate at distant metastatic stage)<sup><xref rid="bibr3-1534735420944491" ref-type="bibr">3</xref></sup> and suffer from a high burden of symptoms and poor quality of life (QoL).
Improving QoL is one of the most important goals for NSCLC patients.<sup><xref rid="bibr4-1534735420944491" ref-type="bibr">4</xref></sup> Chemotherapy remains an essential component of NSCLC treatment even in the
era of precision medicine.<sup><xref rid="bibr5-1534735420944491" ref-type="bibr">5</xref></sup> Unfortunately, its toxic side-effects have a detrimental effect on patients’
QoL<sup><xref rid="bibr6-1534735420944491" ref-type="bibr">6</xref><xref rid="bibr7-1534735420944491" ref-type="bibr"/>-<xref rid="bibr8-1534735420944491" ref-type="bibr">8</xref></sup> and lead to premature treatment
discontinuation.<sup><xref rid="bibr9-1534735420944491" ref-type="bibr">9</xref>,<xref rid="bibr10-1534735420944491" ref-type="bibr">10</xref></sup> Furthermore, lower QoL and depressed mood are associated with
shorter survival among patients.<sup><xref rid="bibr11-1534735420944491" ref-type="bibr">11</xref><xref rid="bibr12-1534735420944491" ref-type="bibr"/><xref rid="bibr13-1534735420944491" ref-type="bibr"/>-<xref rid="bibr14-1534735420944491" ref-type="bibr">14</xref></sup> Therefore, effective
interventions to prevent the decline of QoL in patients undergoing chemotherapy are
critically needed.</p>
              <p>The fruit body of <italic>Ganoderma lucidum</italic> (Leyss ex Fr) Karst, also known
as Reishi mushroom (Lingzhi, <italic>Ganoderma</italic>), is one of the most popular
herbal dietary supplements used by cancer patients around the world.<sup><xref rid="bibr15-1534735420944491" ref-type="bibr">15</xref></sup> Preclinical findings reveal that Reishi mushroom (Lingzhi) has
chemopreventive, tumoricidal, and immunostimulating abilities,<sup><xref rid="bibr16-1534735420944491" ref-type="bibr">16</xref><xref rid="bibr17-1534735420944491" ref-type="bibr"/><xref rid="bibr18-1534735420944491" ref-type="bibr"/><xref rid="bibr19-1534735420944491" ref-type="bibr"/><xref rid="bibr20-1534735420944491" ref-type="bibr"/><xref rid="bibr21-1534735420944491" ref-type="bibr"/><xref rid="bibr22-1534735420944491" ref-type="bibr"/><xref rid="bibr23-1534735420944491" ref-type="bibr"/>-<xref rid="bibr24-1534735420944491" ref-type="bibr">24</xref></sup> increases the overall survival
of tumor bearing mice,<sup><xref rid="bibr25-1534735420944491" ref-type="bibr">25</xref></sup> alleviates chemotherapy-induced side effects,<sup><xref rid="bibr26-1534735420944491" ref-type="bibr">26</xref><xref rid="bibr27-1534735420944491" ref-type="bibr"/>-<xref rid="bibr28-1534735420944491" ref-type="bibr">28</xref></sup> and has a possible synergistic
effect with cisplatin.<sup><xref rid="bibr21-1534735420944491" ref-type="bibr">21</xref></sup> A number of clinical studies have suggested that <italic>G lucidum</italic>
is well tolerated among cancer patients, has potential effects on immune modulation,
and improves QoL and survival outcomes.<sup><xref rid="bibr29-1534735420944491" ref-type="bibr">29</xref><xref rid="bibr30-1534735420944491" ref-type="bibr"/><xref rid="bibr31-1534735420944491" ref-type="bibr"/><xref rid="bibr32-1534735420944491" ref-type="bibr"/>-<xref rid="bibr33-1534735420944491" ref-type="bibr">33</xref></sup> However, these trials often
include various cancer types, with heterogeneous cancer treatment, and have small
sample sizes. More clinical research is needed to determine its safety and efficacy
in lung cancer patients undergoing chemotherapy.</p>
              <p>The Reishi &amp; Privet Formula (RPF) consists of the dried sporederm-broken spores
of the artificially cultivated <italic>G lucidum</italic> Karst and ethanol extracts
and water extracts from the dried mature fruit (glossy Privet fruit, NuZhenzi,
<italic>Ligustri Lucidi Fructus</italic>) of <italic>Ligustrum lucidum</italic>
Ait. Glossy Privet fruit (NuZhenzi) is also widely used by cancer patients in China
as an adjuvant because of its immunomodulatory,<sup><xref rid="bibr34-1534735420944491" ref-type="bibr">34</xref>,<xref rid="bibr35-1534735420944491" ref-type="bibr">35</xref></sup> antitumor,<sup><xref rid="bibr36-1534735420944491" ref-type="bibr">36</xref><xref rid="bibr37-1534735420944491" ref-type="bibr"/>-<xref rid="bibr38-1534735420944491" ref-type="bibr">38</xref></sup> anti-inflammatory, and
hepatoprotective properties<sup><xref rid="bibr39-1534735420944491" ref-type="bibr">39</xref>,<xref rid="bibr40-1534735420944491" ref-type="bibr">40</xref></sup> as demonstrated in in vivo and in vitro studies. This specific
formula aims to achieve better synergetic efficacy and safety than each individual
component.</p>
              <p>RPF was developed from clinical practice in China based on traditional Chinese
medicine theory, which underlies <italic>Jun-Chen-Zuo-Shi</italic> medicinal
compatibility strategy. Reishi mushroom (Lingzhi) spores, the principal component
(<italic>Jun</italic> herb) of RPF, perform the primary action of treating qi
deficiency. Glossy Privet fruit (NuZhenzi), the adjuvant component
(<italic>Chen</italic> herb) in treating yin deficiency, synergizes with
<italic>Jun</italic> to strengthen its therapeutic effects and reduce or
eliminate possible adverse effects. NSCLC patients undergoing chemotherapy usually
demonstrate a cluster of symptoms<sup><xref rid="bibr41-1534735420944491" ref-type="bibr">41</xref>,<xref rid="bibr42-1534735420944491" ref-type="bibr">42</xref></sup> (eg, fatigue, drowsiness, loss
of appetite, shortness of breath, cough, anxiety, insomnia, and dry mouth), which
may be diagnosed as a qi-yin deficiency symptom pattern.<sup><xref rid="bibr43-1534735420944491" ref-type="bibr">43</xref></sup> The RPF formula is designed to tonify energy, reinforce deficiency, and
relieve symptoms in a patient-centered manner for those with qi-yin deficiency
symptom pattern.</p>
              <p>Based on previous clinical experience, preclinical and clinical research data, RPF
may play a role of improving cancer patients’ QoL in multiple ways. However,
clinical studies of RPF are lacking. We proposed to investigate the preliminary
efficacy and safety of RPF for NSCLC patients undergoing chemotherapy to inform the
development and design of future adequately powered randomized controlled trials
(RCTs) to test the specific efficacy and safety of this product.</p>
            </sec>
            <sec sec-type="methods" id="section6-1534735420944491">
              <title>Patients and Methods</title>
              <sec id="section7-1534735420944491">
                <title>Study Design</title>
                <p>This was a phase II randomized, double-blind, placebo-controlled clinical trial
conducted at 8 cancer research centers in China (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1534735420944491">Appendix 1; available online</ext-link>). The independent ethics committees
at each center approved the study (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1534735420944491">Appendix 1</ext-link>).</p>
              </sec>
              <sec id="section8-1534735420944491">
                <title>Participants</title>
                <p>Eligible patients were 18 to 75 years of age with confirmed NSCLC and greater
than 3 months of life expectancy who were scheduled to receive at least 2 cycles
of chemotherapy with either paclitaxel plus cisplatin (TP, paclitaxel 135
mg/m<sup>2</sup> on day 1, cisplatin 75 mg/m<sup>2</sup> on day 2, every 3
weeks) or paclitaxel plus carboplatin (TC, paclitaxel 200 mg/m<sup>2</sup> on
day 1, carboplatin AUC [area under the curve] 6 on day 1, every 3 weeks).</p>
                <p>Exclusion criteria were as follows: (1) Karnofsky performance status &lt; 70; (2)
laboratory values obtained prior to randomization: white blood cell &lt;3 ×
10<sup>9</sup>/L, absolute neutrophil count &lt;1.5 × 10<sup>9</sup>/L,
platelet &lt;75 × 10<sup>12</sup>/L, hemoglobin &lt;8 g/dL, creatinine &gt;1.5 ×
upper normal limit (UNL), bilirubin &gt;2 × UNL, aspartate aminotransferase,
alanine aminotransferase, or alkaline phosphatase &gt;2.5 × UNL (&gt;5 × UNL in
presence of liver metastases); (3) severe/uncontrolled systemic diseases,
including gastrointestinal dysfunction, bleeding, cardiac dysfunction, endocrine
dysfunction, or infection; (4) significant cognitive impairment or psychiatric
disturbance; (5) allergy to RPF or active ingredients; (6) use of other
investigational drug within 30 days before study entry; and (7) any relevant
condition potentially interfering with study evaluation. We recorded concomitant
medications taken during the study.</p>
                <p>We recruited subjects via media and print advertisements. Patients provided
written informed consent before participating in the study. A trained study
coordinator made initial contact with the subjects; all study-related procedures
were performed at 8 cancer research centers in China.</p>
              </sec>
              <sec id="section9-1534735420944491">
                <title>Randomization and Blinding</title>
                <p>Randomization was done via a computer-generated list and stratified by center. An
independent biostatistician with no clinical involvement in the trial prepared
the randomization sequence and allocation concealment. Sealed envelopes
containing allocation assignment and packaged medication/placebo were sent to
each of the 8 centers. Investigators enrolled patients at each center. The
blinded pharmacist at each center provided the study team with ready-to-use
blinded medication/placebo according to enrollment order.</p>
                <p>All investigators, staff, participants, and sponsor personnel or delegate(s) who
were involved in the treatment administration or clinical evaluation of the
subjects were blinded to the group assignments. The chemotherapy agents were
open-label. Researchers were required to document the chemotherapy regimen
patients received prior to randomization. Study medications were supplied in a
blinded manner as RPF/placebo capsules and were packaged identically. Each
patient received 2 boxes of RPF or placebo, one for the first treatment period
(day 1 to day 21) and another for the second treatment period (day 22 to day
42).</p>
              </sec>
              <sec id="section10-1534735420944491">
                <title>Intervention</title>
                <p>Patients scheduled to receive either TP or TC were randomly assigned (3:1 ratio)
to receive oral RPF (3.36 g/day) or placebo daily for 6 weeks concurrent with
their chemotherapy. Patients were instructed to take 4 RPF/placebo capsules
orally 3 times a day (in the morning, at noon, and in the afternoon) for a total
of 3.36 g/day. Each RPF capsule (Nanjing Zhongke Pharmaceutical Co, Ltd, batch
number B20160401) weighed 0.28 g and contained 0.15 g of sporederm-broken Reishi
mushroom (Lingzhi) spore, 0.11 g of glossy Privet fruit (NuZhenzi) extract, 5%
crospovidone, and 2% silica. Each capsule was standardized to contain &gt;1%
polysaccharide and &gt;2.0 mg of oleanolic acid
(C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>). It was manufactured in
accordance with good manufacturing practices (Certificate of GMP No. JS20160640)
and tested for batch-to-batch consistency according to the State Pharmacopoeia
of the People’s Republic of China (2000).<sup><xref rid="bibr44-1534735420944491" ref-type="bibr">44</xref></sup> Reishi mushroom (Lingzhi) spore is the dried spore of <italic>G
lucidium</italic> Karst, which is collected and dried when the artificially
cultivated plants grow mature and release spores. Glossy Privet fruit (NuZhenzi)
is the dried mature fruit of <italic>Ligustrum lucidum</italic> Ait, which is
harvested in winter when the fruits are mature. Glossy Privet fruit (NuZhenzi)
was extracted using 70% ethanol and the residual was further extracted using
water. The extracts were then combined and mixed evenly with the shell-broken
Reishi mushroom (Lingzhi) spore. After drying, an appropriate amount of
microcrystalline cellulose was added, and the mixture was granulated and dried.
Crospovidone (5%) and silica (2%) were added to make the capsule. The placebo
capsule (Nanjing Zhongke Pharmaceutical Co, Ltd) was filled with 52.8% caramel
color, 40.7% rice powder, and 6.5% brown iron oxide pigment. The placebo pill
also weighed 0.28 g and was packed in identical capsules as the RPF. The study
medication and placebo were stored in a locked cabinet at room temperature at
each research center.</p>
                <p>The sporederm-broken <italic>Ganoderma</italic> spore micrographs produced by
electron microscopy are shown in <xref ref-type="fig" rid="fig1-1534735420944491">Figure 1a</xref>. The RPF was subjected to
high-performance liquid chromatography (HPLC); a HPLC fingerprint of the extract
is shown in <xref ref-type="fig" rid="fig1-1534735420944491">Figure
1b</xref>.</p>
                <fig id="fig1-1534735420944491" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>(a) Reishi &amp; Privet Formula (RPF) micrographs. (A) Raw
<italic>Ganoderma</italic> spore. (B) Raw <italic>Ganoderma</italic>
spore. (C) Sporederm-broken <italic>Ganoderma</italic> spore. (D)
Sporederm-broken <italic>Ganoderma</italic> spore. (b) HPLC fingerprint
of the Reishi &amp; Privet formula. HPLC, high-performance liquid
chromatography.</p>
                  </caption>
                  <graphic xlink:href="10.1177_1534735420944491-fig1"/>
                </fig>
              </sec>
              <sec id="section11-1534735420944491">
                <title>Outcomes</title>
                <p>The main outcome was the 36-item self-report Functional Assessment of Cancer
Therapy–Lung (FACT-L 4.0,<sup><xref rid="bibr45-1534735420944491" ref-type="bibr">45</xref>,<xref rid="bibr46-1534735420944491" ref-type="bibr">46</xref></sup> Chinese version), a
disease-specific questionnaire including the 27-item FACT-G (core instrument),
and the 9-item Lung Cancer Subscale (LCS). The total FACT-G score is calculated
by summing the subscale scores of physical well-being, social/family well-being,
emotional well-being, and functional well-being. A total FACT-L score is
obtained by summing the FACT-G score with the LCS (2 of the 9 items are not used
in the scoring), thereby augmenting the FACT-G with lung cancer-specific QoL
information. We also calculated a 21-item Trial Outcome Index (TOI) by summing
physical well-being, functional well-being, and the LCS. All questions are rated
on 5-point Likert-type scales ranging from 0 (not at all) to 4 (very much). A
higher score indicates better QoL or fewer symptoms. We collected all
patient-reported outcome measures at baseline (before starting treatment), and
at 3 and 6 weeks.</p>
                <p>Investigators evaluated adverse events each week and graded them according to the
Common Terminology Criteria for Adverse Events version 4.0.<sup><xref rid="bibr47-1534735420944491" ref-type="bibr">47</xref></sup> Symptomatic adverse events evaluated during the treatment included
fatigue, insomnia, decreased appetite, constipation, diarrhea, bloating, and
nausea. We evaluated white blood cell, neutrophil, hemoglobin, and platelets in
the peripheral blood at baseline and every week after the start of chemotherapy.
We evaluated creatinine, aspartate aminotransferase, alanine aminotransferase,
and alkaline phosphatase in the peripheral blood at baseline, 3 weeks, and 6
weeks.</p>
              </sec>
              <sec id="section12-1534735420944491">
                <title>Statistical Analysis</title>
                <p>This study was designed to estimate the initial effect size and safety. It is
important to note that statistical significance is not the primary goal in
determining the success of a phase II trial. We estimated that with 84 patients,
the study would have 80% power to detect a significant between-group difference
in the change in total FACT-L score from baseline to 6 weeks, with a large
effect size of 0.7 SD.<sup><xref rid="bibr48-1534735420944491" ref-type="bibr">48</xref></sup> The primary outcome of the pilot study was change from baseline to 6
weeks in the FACT-L total score.</p>
                <p>Our analyses were guided by intention-to-treat principles. We used the
χ<sup>2</sup> test to compare baseline variables between groups. Because our
primary and secondary outcome measures were repeated measures over time, we
assessed differences in changes from baseline to week 3 and week 6 using mixed
effect models. We treated time and treatment as categorical variables and
included a random intercept term in the mixed effect model. Tests of
intention-to-treat differences between intervention arms with regard to the
change were based on time-intervention interactions in the mixed effect models.
We have presented results as between-group differences with 95% confidence
intervals (CIs). All statistical tests were 2-sided.</p>
                <p>Statistical significance was set at the &lt;.05 level. All statistical analysis
was conducted using STATA (version 15.0; STATA Corporation) and SAS (version
9.4; SAS Institute).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section13-1534735420944491">
              <title>Results</title>
              <sec id="section14-1534735420944491">
                <title>Baseline Characteristics of the Participants</title>
                <p>Between February 2017 and January 2018, we enrolled 82 participants across 8
cancer centers in China. In the RFT group, 80% (N = 49) completed all
study-related activities; 76% (N = 16) in the placebo group completed all
study-related activities (<xref ref-type="fig" rid="fig2-1534735420944491">Figure 2</xref>). In the RFT group, 2 out of 61 (3.3%) discontinued therapy
due to adverse events compared with 1 out of 21 (4.8%) in the placebo group. In
addition, 4 (6.6%) patients in the RPF group and 2 (9.5%) patients in the
placebo group withdrew consent; 4 (6.6%) patients in RPF and 2 (9.5%) in placebo
were lost to follow-up; and the study PI withdrew 2 (3.3%) patients from the RPF
group due to protocol violation (<xref ref-type="fig" rid="fig2-1534735420944491">Figure 2</xref>).</p>
                <fig id="fig2-1534735420944491" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>CONSORT diagram.</p>
                  </caption>
                  <graphic xlink:href="10.1177_1534735420944491-fig2"/>
                </fig>
                <p>Patient demographic and clinical characteristics were well balanced between the 2
treatment groups and are summarized in <xref rid="table1-1534735420944491" ref-type="table">Table 1</xref>. Of the 82 randomized patients,
the median age was 59 years (range = 29-75 years), 58 (71%) were males, and the
median Karnofsky performance score was 90 (range = 70-100). Among the
participants, 49 (60%) had a diagnosis of non-squamous cell lung cancer. The
majority (n = 56, 68%) had advanced (stages IIIB and IV) lung cancer, 48 (59%)
had no prior history of chemotherapy before enrollment into the study, 48 (59%)
received TP, and 34 (41%) received TC as a chemotherapy regimen. The mean FACT-L
total score was 89.1 and the mean FACT-G score was 70.5.</p>
                <table-wrap id="table1-1534735420944491" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Baseline Patient Characteristics.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_1534735420944491-table1"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">Total (N = 82)</th>
                          <th align="center" rowspan="1" colspan="1">RPF (N = 61)</th>
                          <th align="center" rowspan="1" colspan="1">Placebo (N = 21)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Age in years, median (range)</td>
                          <td rowspan="1" colspan="1">59 (29-75)</td>
                          <td rowspan="1" colspan="1">59 (29-75)</td>
                          <td rowspan="1" colspan="1">55 (39-70)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;65, n (%)</td>
                          <td rowspan="1" colspan="1">66 (80)</td>
                          <td rowspan="1" colspan="1">48 (79)</td>
                          <td rowspan="1" colspan="1">18 (86)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ≥65, n (%)</td>
                          <td rowspan="1" colspan="1">16 (20)</td>
                          <td rowspan="1" colspan="1">13 (21)</td>
                          <td rowspan="1" colspan="1">3 (14)</td>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">Gender, n (%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Male</td>
                          <td rowspan="1" colspan="1">58 (71)</td>
                          <td rowspan="1" colspan="1">45 (74)</td>
                          <td rowspan="1" colspan="1">13 (62)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Female</td>
                          <td rowspan="1" colspan="1">24 (29)</td>
                          <td rowspan="1" colspan="1">16 (26)</td>
                          <td rowspan="1" colspan="1">8 (38)</td>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">Cancer stage, n (%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Stage I</td>
                          <td rowspan="1" colspan="1">5 (6)</td>
                          <td rowspan="1" colspan="1">4 (7)</td>
                          <td rowspan="1" colspan="1">1 (5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Stage II</td>
                          <td rowspan="1" colspan="1">15 (18)</td>
                          <td rowspan="1" colspan="1">11 (18)</td>
                          <td rowspan="1" colspan="1">4 (19)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Stage IIIA</td>
                          <td rowspan="1" colspan="1">6 (7)</td>
                          <td rowspan="1" colspan="1">4 (7)</td>
                          <td rowspan="1" colspan="1">2 (9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Stage IIIB</td>
                          <td rowspan="1" colspan="1">14 (17)</td>
                          <td rowspan="1" colspan="1">9 (14)</td>
                          <td rowspan="1" colspan="1">5 (24)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Stage IV</td>
                          <td rowspan="1" colspan="1">42 (51)</td>
                          <td rowspan="1" colspan="1">33 (54)</td>
                          <td rowspan="1" colspan="1">9 (43)</td>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">Histology, n (%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Squamous</td>
                          <td rowspan="1" colspan="1">32 (40)</td>
                          <td rowspan="1" colspan="1">24 (40)</td>
                          <td rowspan="1" colspan="1">8 (38)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Non-squamous</td>
                          <td rowspan="1" colspan="1">49 (60)</td>
                          <td rowspan="1" colspan="1">36 (60)</td>
                          <td rowspan="1" colspan="1">13 (62)</td>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">Chemotherapy scheme, n (%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Paclitaxel plus cisplatin (TP)</td>
                          <td rowspan="1" colspan="1">48 (59)</td>
                          <td rowspan="1" colspan="1">35 (57)</td>
                          <td rowspan="1" colspan="1">13 (62)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Paclitaxel plus carboplatin (TC)</td>
                          <td rowspan="1" colspan="1">34 (41)</td>
                          <td rowspan="1" colspan="1">26 (43)</td>
                          <td rowspan="1" colspan="1">8 (38)</td>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">Past chemotherapy<sup><xref ref-type="table-fn" rid="table-fn2-1534735420944491">a</xref></sup>, n (%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">34 (41)</td>
                          <td rowspan="1" colspan="1">25 (41)</td>
                          <td rowspan="1" colspan="1">9 (43)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">48 (59)</td>
                          <td rowspan="1" colspan="1">36 (59)</td>
                          <td rowspan="1" colspan="1">12 (57)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">KPS score, median (range)</td>
                          <td rowspan="1" colspan="1">90 (70-100)</td>
                          <td rowspan="1" colspan="1">90 (70-90)</td>
                          <td rowspan="1" colspan="1">90 (70-100)</td>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">FACT-L, mean (SD)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> FACT-L total</td>
                          <td rowspan="1" colspan="1">89.1 (17.1)</td>
                          <td rowspan="1" colspan="1">88.1 (16.8)</td>
                          <td rowspan="1" colspan="1">91.9 (18.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> FACT-G total</td>
                          <td rowspan="1" colspan="1">70.5 (14.4)</td>
                          <td rowspan="1" colspan="1">69.7 (14.4)</td>
                          <td rowspan="1" colspan="1">72.7 (14.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Trial Outcome index<sup><xref ref-type="table-fn" rid="table-fn3-1534735420944491">b</xref></sup></td>
                          <td rowspan="1" colspan="1">53.6 (11.3)</td>
                          <td rowspan="1" colspan="1">52.8 (10.5)</td>
                          <td rowspan="1" colspan="1">56.1 (13.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Lung cancer subscale</td>
                          <td rowspan="1" colspan="1">18.6 (4.2)</td>
                          <td rowspan="1" colspan="1">18.3 (4.0)</td>
                          <td rowspan="1" colspan="1">19.2 (4.8)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Physical well-being</td>
                          <td rowspan="1" colspan="1">20.8 (4.7)</td>
                          <td rowspan="1" colspan="1">20.6 (4.7)</td>
                          <td rowspan="1" colspan="1">21.6 (4.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Social/family well-being</td>
                          <td rowspan="1" colspan="1">20.0 (4.9)</td>
                          <td rowspan="1" colspan="1">19.9 (4.5)</td>
                          <td rowspan="1" colspan="1">20.0 (5.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Emotional well-being</td>
                          <td rowspan="1" colspan="1">15.5 (4.9)</td>
                          <td rowspan="1" colspan="1">15.4 (4.9)</td>
                          <td rowspan="1" colspan="1">15.8 (4.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Functional well-being</td>
                          <td rowspan="1" colspan="1">14.3 (2.5)</td>
                          <td rowspan="1" colspan="1">13.9 (4.9)</td>
                          <td rowspan="1" colspan="1">15.2 (6.0)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn1-1534735420944491">
                      <p>Abbreviations: RPF, Reishi &amp; Privet formula; KPS, Karnofsky
performance score; FACT-L, Functional Assessment of Cancer
Therapy–Lung; FACT-G, FACT-General.</p>
                    </fn>
                    <fn id="table-fn2-1534735420944491">
                      <label>a</label>
                      <p>Past chemotherapy means whether patients had received any
chemotherapy before this study.</p>
                    </fn>
                    <fn id="table-fn3-1534735420944491">
                      <label>b</label>
                      <p>Trial Outcome Index = physical well-being + functional well-being +
lung cancer subscale.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section15-1534735420944491">
                <title>Quality of Life</title>
                <p>We have presented our results in <xref rid="table2-1534735420944491" ref-type="table">Table 2</xref>. Overall, the RPF group showed
a better QoL measured by FACT-L total score (higher score indicates better QoL)
compared with the placebo group from baseline to 6 weeks of treatment, although
not statistically significant (<italic>P</italic> = .086 for treatment and time
interaction term). At week 3 after the first cycle of chemotherapy, the RPF
group reported a 7.99 (95% CI = 0.9 to 15.0) point higher in the FACT-L total
score than the placebo group. At week 6 after 2 cycles of chemotherapy, the
between group difference in the FACT-L total change score was 4.63 (95% CI =
−2.5 to 11.7), favoring the RPF group (see <xref ref-type="fig" rid="fig3-1534735420944491">Figure 3</xref>). We observed a similar trend in
the FACT-G score and the emotional well-being domain score change. The RPF group
showed a greater increase in the FACT-G score from baseline than the placebo
group after 6 weeks with a <italic>P</italic> value of .05 approaching
statistical significance. At week 3, the between group difference in the FACT-G
score was 7.46 (95% CI = 1.5 to 13.4) favoring the RPF group. At week 6, the RPF
group’s change from baseline in FACT-G score was still greater than the placebo
group with a between group difference of 3.88 (95% CI = −2.0 to 9.8). In the
emotional well-being domain, at week 3, the RPF group showed a 1.97 (95% CI =
0.2 to 3.7) point greater increase than the placebo group. At week 6, this trend
was maintained with a between group difference of 0.8 (95% CI = −1.0 to 2.6)
favoring the RPF group with an overall <italic>P</italic> value of .090 for the
treatment and time interaction term.</p>
                <table-wrap id="table2-1534735420944491" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Mean Change in FACT-L Scores From Baseline to 6 Weeks.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_1534735420944491-table2"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="2" colspan="1">Outcomes</th>
                          <th align="center" rowspan="2" colspan="1">Visit</th>
                          <th align="center" colspan="2" rowspan="1">Change from baseline, mean (95%
CI)</th>
                          <th align="center" rowspan="1" colspan="1">Between group differences, mean (95% CI)</th>
                          <th align="center" rowspan="2" colspan="1">
                            <italic>P</italic>
                            <sup>
                              <xref ref-type="table-fn" rid="table-fn5-1534735420944491">a</xref>
                            </sup>
                          </th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">RPF (N = 52)</th>
                          <th align="center" rowspan="1" colspan="1">Placebo (N = 17)</th>
                          <th align="center" rowspan="1" colspan="1">RPF versus placebo</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="3" colspan="1">FACT-L<sup><xref ref-type="table-fn" rid="table-fn6-1534735420944491">b</xref></sup></td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.086</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">2.39 (−1.10 to 5.88)</td>
                          <td rowspan="1" colspan="1">−5.60 (−11.7 to 0.5)</td>
                          <td rowspan="1" colspan="1">7.99 (0.9 to 15.0)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">−0.05 (−3.62 to 3.52)</td>
                          <td rowspan="1" colspan="1">−4.68 (−10.8 to 1.5)</td>
                          <td rowspan="1" colspan="1">4.63 (2.5 to 11.7)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">Physical well-being</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.32</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">0.23 (−0.75 to 1.21)</td>
                          <td rowspan="1" colspan="1">−0.84 (−2.6 to 0.9)</td>
                          <td rowspan="1" colspan="1">1.08 (−0.9 to 3.1)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">−0.83 (−1.83 to 0.17)</td>
                          <td rowspan="1" colspan="1">0.38 (−2.1 to 1.4)</td>
                          <td rowspan="1" colspan="1">−0.45 (−2.5 to 1.6)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">Social/family well-being</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.41</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">0.16 (−1.25 to 1.57)</td>
                          <td rowspan="1" colspan="1">−1.5 (−4.0 to 1.0)</td>
                          <td rowspan="1" colspan="1">1.66 (−1.2 to 4.5)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">0.29 (−1.16 to 1.74)</td>
                          <td rowspan="1" colspan="1">−1.4 (−3.9 to 1.1)</td>
                          <td rowspan="1" colspan="1">1.69 (−1.2 to 4.6)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">Emotional well-being</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.090</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">1.02 (0.14 to 1.90)</td>
                          <td rowspan="1" colspan="1">−0.95 (−2.5 to 0.6)</td>
                          <td rowspan="1" colspan="1">1.97 (0.2 to 3.7)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">0.68 (−0.22 to 1.58)</td>
                          <td rowspan="1" colspan="1">−0.13 (−1.7 to 1.4)</td>
                          <td rowspan="1" colspan="1">0.8 (−1.0 to 2.6)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">Functional well-being</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.10</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">0.52 (−0.79 to 1.83)</td>
                          <td rowspan="1" colspan="1">−2.38 (−4.7 to −0.1)</td>
                          <td rowspan="1" colspan="1">2.90 (0.2 to 5.6)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">−0.64 (−1.99 to 0.71)</td>
                          <td rowspan="1" colspan="1">−2.43 (−4.7 to −0.1)</td>
                          <td rowspan="1" colspan="1">1.79 (−0.9 to 4.5)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">Lung cancer subscale</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.80</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">0.52 (−0.58 to 1.62)</td>
                          <td rowspan="1" colspan="1">−0.03 (−2.0 to 1.9)</td>
                          <td rowspan="1" colspan="1">0.55 (−1.7 to 2.8)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">0.44 (−0.68 to 1.56)</td>
                          <td rowspan="1" colspan="1">−0.28 (−2.2 to 1.6)</td>
                          <td rowspan="1" colspan="1">0.73 (−1.5 to 2.9)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">Trial outcome index<sup><xref ref-type="table-fn" rid="table-fn7-1534735420944491">c</xref></sup></td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.18</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">1.21 (−1.10 to 3.52)</td>
                          <td rowspan="1" colspan="1">−3.21 (−7.3 to 0.8)</td>
                          <td rowspan="1" colspan="1">4.42 (−0.2 to 9.1)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">−1.09 (−3.46 to 1.28)</td>
                          <td rowspan="1" colspan="1">−3.17 (−7.2 to 0.9)</td>
                          <td rowspan="1" colspan="1">2.08 (−2.6 to 6.8)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="3" colspan="1">FACT-G<sup><xref ref-type="table-fn" rid="table-fn8-1534735420944491">d</xref></sup></td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">.050</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 3</td>
                          <td rowspan="1" colspan="1">1.90 (−1.02 to 4.82)</td>
                          <td rowspan="1" colspan="1">−5.56 (−10.7 to −0.4)</td>
                          <td rowspan="1" colspan="1">7.46 (1.5 to 13.4)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Week 6</td>
                          <td rowspan="1" colspan="1">−0.48 (−3.46 to 2.50)</td>
                          <td rowspan="1" colspan="1">−4.36 (−9.5 to 0.8)</td>
                          <td rowspan="1" colspan="1">3.88 (−2.0 to 9.8)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn4-1534735420944491">
                      <p>Abbreviations: FACT-L, Functional Assessment of Cancer Therapy–Lung,
CI, confidence interval; RPF, Reishi &amp; Privet formula; FACT-G,
FACT-General.</p>
                    </fn>
                    <fn id="table-fn5-1534735420944491">
                      <label>a</label>
                      <p>Mixed effect <italic>P</italic>-value from interaction term between
visit and treatment.</p>
                    </fn>
                    <fn id="table-fn6-1534735420944491">
                      <label>b</label>
                      <p>FACT-L = FACT-G + LCS.</p>
                    </fn>
                    <fn id="table-fn7-1534735420944491">
                      <label>c</label>
                      <p>Trial Outcome Index = physical well-being + functional well-being +
lung cancer subscale.</p>
                    </fn>
                    <fn id="table-fn8-1534735420944491">
                      <label>d</label>
                      <p>FACT-G = physical well-being + social/family well-being + emotional
well-being + functional well-being.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig id="fig3-1534735420944491" orientation="portrait" position="float">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Mean change in FACT-L (Functional Assessment of Cancer Therapy–Lung)
total scores from baseline to 6 weeks.</p>
                    <p>RPF, Reishi &amp; Privet formula.</p>
                  </caption>
                  <graphic xlink:href="10.1177_1534735420944491-fig3"/>
                </fig>
              </sec>
              <sec id="section16-1534735420944491">
                <title>Safety</title>
                <p>Adverse events were generally mild and moderate in severity and were similar
between treatment groups. The most frequently reported chemotherapy-related
adverse events were gastrointestinal, neutropenia, anemia, fatigue, and
decreased appetite. Two adverse events (abdominal bloating and insomnia) were
classified as possibly related to the RPF study drug. Among patients who
reported fatigue after the start of chemotherapy in the RPF group, fatigue
either improved or remained unchanged in 13 out of 15 (87%) patients. However,
in the placebo group only 1 in 3 (33%) patients who experienced fatigue at the
start of the chemotherapy reported improved or unchanged fatigue. No group
differences were observed in the frequency and severity of other adverse events
such as neutropenia, anemia, thrombocytopenia, and hepatobiliary and renal
disorders.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section17-1534735420944491">
              <title>Discussion</title>
              <p>In this phase II, randomized, double-blind, placebo-controlled clinical trial, we
evaluated the preliminary efficacy and safety of RPF for maintaining QoL among
patients with NSCLC undergoing chemotherapy. Participants who received RPF had
nonsignificant higher QoL scores than those who were randomized to the placebo
group. We observed a greater increase in the RPF group’s week 3 and week 6 FACT-L,
FACT-G, and emotional well-being scores compared with the placebo group. More
patients in the RPF group who experienced fatigue at the beginning of chemotherapy
were able to either maintain or reduce their fatigue during chemotherapy than those
in the placebo group. The herbal formula was also well tolerated with few related
adverse events. To our knowledge, this is the first clinical study of this Reishi
mushroom-based herbal formula targeting QoL during chemotherapy in people with NSCLC
and assessed by a well-established patient-reported outcome (FACT-L 4.0).</p>
              <p>It is important to place our findings in the context of prior research involving
Reishi mushroom products. Gao et al<sup><xref rid="bibr33-1534735420944491" ref-type="bibr">33</xref></sup> found the polysaccharide fractions extracted from <italic>G lucidum</italic>
enhanced immune responses (cytokines, T-cell subsets, mitotic response to
phytohemagglutinin, and natural killer activity) in advanced cancer patients. A
pilot study suggested that spore powder of <italic>G lucidum</italic> may have
beneficial effects on cancer-related fatigue and QoL, but the study population was
breast cancer patients undergoing endocrine therapy.<sup><xref rid="bibr31-1534735420944491" ref-type="bibr">31</xref></sup> Two systematic reviews indicated <italic>G lucidum</italic> might have
potential benefits on overall survival, tumor response, immunity stimulation, and
Karnofsky performance status.<sup><xref rid="bibr29-1534735420944491" ref-type="bibr">29</xref>,<xref rid="bibr30-1534735420944491" ref-type="bibr">30</xref></sup> We contributed to the
literature by suggesting the potential effect of this Reishi mushroom-based formula
in maintaining QoL and emotional wellbeing for NSCLC patients undergoing
chemotherapy.</p>
              <p>Considering that the majority of the study population was advanced NSCLC patients
undergoing chemotherapy, deterioration in QoL was expected. The results of the
Eastern Cooperative Oncology Group trial showed that chemotherapy regimens such as
TP demonstrated significant decreases in QoL scores over 6 months. Their study<sup><xref rid="bibr6-1534735420944491" ref-type="bibr">6</xref></sup> used the TOI to measure the change in QoL (TOI is a subscale of the FACT-L
and an indicator of the physical component of QoL). Of patients treated with TP, 36%
reported worsened TOI of ≥5 units at week 6. TOI and FACT-L total scores decreased
8.3 and −9.9 points, respectively, at 6 months after receiving the first course of
chemotherapy.</p>
              <p>Although our study did not reach statistical significance, the magnitude of
difference in QoL has potential clinical implications. The patients in the RPF group
maintained FACT-L scores from baseline to 6 weeks (mean change = −0.05, 95% CI =
−3.62 to 3.52), while patients in the placebo group had decreased QoL (mean change =
−4.68, 95% CI = −10.8 to 1.5). In the RPF group, 38 (62%) patients showed
improvement in the FACT-L at week 6, while only 9 (43%) patients in the placebo
group showed improvement in FACT-L score. Meanwhile, the potential benefit over the
placebo group in the FACT-G total score (<italic>P</italic> = .050) and emotional
well-being (<italic>P</italic> = .090) was also consistent as seen in the FACT-L
total scores. Compared with the results of the Eastern Cooperative Oncology Group
trial,<sup><xref rid="bibr6-1534735420944491" ref-type="bibr">6</xref>,<xref rid="bibr49-1534735420944491" ref-type="bibr">49</xref></sup> our study
demonstrated that with RPF treatment, the FACT-L and FACT-G total scores did not
decrease, and in fact showed some increase over time. This suggests that RPF might
have the potential to improve QoL of lung cancer patients going through active
treatments, a promising clinical benefit that requires further investigation.</p>
              <p>Our study provided preliminary safety and tolerability data for the concurrent use of
RPF with chemotherapy. RPF-related adverse events were rare and mild. A
meta-analysis of clinical results showed similar evidence that Reishi mushroom
(Lingzhi) was generally well tolerated with minimal side effects including nausea
and insomnia, and no reports of significant hematological or hepatological toxicity.<sup><xref rid="bibr30-1534735420944491" ref-type="bibr">30</xref></sup> Although we did not observe any sign of RPF preventing objective adverse
events such as neutropenia, anemia, or thrombocytopenia, we did observe that a
greater proportion of patients in the RPF group who experienced fatigue at the start
of chemotherapy were able to either maintain or reduce their fatigue during the rest
of treatment. This might indicate that RPF has the potential to reduce
chemotherapy-induced fatigue. One pilot RCT of 48 breast cancer patients undergoing
endocrine therapy in a short-term (4 week) intervention study<sup><xref rid="bibr31-1534735420944491" ref-type="bibr">31</xref></sup> also suggests that the spore powder of <italic>G lucidum</italic> may have
beneficial effects on the physical well-being domain and fatigue subscale as
assessed by FACT-F and the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Version 3.0 questionnaires. Future larger
trials are needed to provide more definitive data of the safety of RPF and its
impact on chemotherapy-related QoL measures.</p>
              <sec id="section18-1534735420944491">
                <title>Limitations</title>
                <p>Our study has several limitations. This trial was designed as an unregistered
phase II trial with a small sample size, which prevented us from providing
definitive evidence on the safety and efficacy of RPF for QoL. Based on the
knowledge gained from this trial, future prospectively registered and adequately
powered trials are needed to verify the preliminary effects identified in this
study. QoL and symptom burden typically gets worse within 1 week of chemotherapy
infusion and gradually improve over the next few weeks; therefore, our
infrequent patient-reported outcomes assessment may not have fully captured the
impact of RPF on QoL. Finally, our study was conducted among a Chinese
population; studies in other populations are needed to increase its
generalizability.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="section19-1534735420944491">
              <title>Conclusions</title>
              <p>Rigorous clinical research is essential in building the evidence base for the safe
and effective use of herbal medicine for cancer patients.<sup><xref rid="bibr50-1534735420944491" ref-type="bibr">50</xref></sup> Our double-blinded RCT found preliminary efficacy and safety of RPF, a Reishi
mushroom herbal product, in improving QoL for patients with NSCLC undergoing
chemotherapy. These preliminary findings need to be verified in adequately powered,
well-designed clinical trials to establish RPF’s definitive safety and efficacy.</p>
            </sec>
            <sec sec-type="supplementary-material" id="section20-1534735420944491" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material content-type="local-data" id="suppl1-1534735420944491">
                <caption>
                  <title>4_Reishi_appendix_1_April_24_2020_Clean – Supplemental material for
Preliminary Efficacy and Safety of Reishi &amp; Privet Formula on Quality of
Life Among Non–Small Cell Lung Cancer Patients Undergoing Chemotherapy: A
Randomized Placebo-Controlled Trial</title>
                </caption>
                <media xlink:href="4_Reishi_appendix_1_April_24_2020_Clean.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, 4_Reishi_appendix_1_April_24_2020_Clean for Preliminary
Efficacy and Safety of Reishi &amp; Privet Formula on Quality of Life Among
Non–Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized
Placebo-Controlled Trial by Jie Liu, Jun J. Mao, Susan Qing Li and Hongsheng Lin
in Integrative Cancer Therapies</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank Nanjing Zhongke Pharmaceutical Co, Ltd (Nanjing, China) for providing the
standardized RRF and placebo for the study. We would like to thank all study staff
and participants. We thank Christina Seluzicki for her editorial assistance in the
preparation of this manuscript.</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement">
                <p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: The authors
report grant funding from Nanjing Zhongke Pharmaceutical Co, Ltd. Dr. Mao has
also received grant funding unrelated to this study from Tibet Cheezheng Tibetan
Medicine Co, Ltd.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the Nanjing Zhongke Pharmaceutical Co, Ltd. Dr. Liu and Dr. Lin are
supported by International Cooperative Research in Chinese Medicine of the
National Administration of Traditional Chinese Medicine of the People’s Republic
of China (Grant Number GZYYGJ2017008). Dr. Mao is supported by the Memorial
Sloan Kettering Cancer Center’s Translational and Integrative Medicine Research
Fund and a National Institutes of Health/National Cancer Institute Cancer Center
grant (Grant Number P30 CA008748). The funding agencies had no role in the
design, conduct, or analysis of the study, or the decision to submit the
manuscript for publication.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iD:</bold> Jie Liu <inline-graphic xlink:href="10.1177_1534735420944491-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-6112-2947">https://orcid.org/0000-0002-6112-2947</ext-link></p>
              </fn>
              <fn fn-type="supplementary-material">
                <p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-1534735420944491">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries</article-title>.
<source>CA Cancer J Clin</source>.
<year>2018</year>;<volume>68</volume>:<fpage>394</fpage>-<lpage>424</lpage>.<pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation>
              </ref>
              <ref id="bibr2-1534735420944491">
                <label>2</label>
                <mixed-citation publication-type="web"><collab>American Society of Clinical Oncology</collab>. <article-title>Non-small
cell lung cancer survival rates, by stage</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html">https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html</ext-link>.</mixed-citation>
              </ref>
              <ref id="bibr3-1534735420944491">
                <label>3</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Howlader</surname><given-names>N</given-names></name><name><surname>Noone</surname><given-names>AM</given-names></name><name><surname>Krapcho</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><source>SEER Cancer Statistics Review,
1975-2014</source>. <publisher-name>National Cancer
Institute</publisher-name>; <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="bibr4-1534735420944491">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Hollen</surname><given-names>PJ</given-names></name><name><surname>Msaouel</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>BV</given-names></name><name><surname>Petersen</surname><given-names>J.</given-names></name></person-group><article-title>An evidence-based determination of issues affecting quality of
life and patient-reported outcomes in lung cancer: results of a survey of
660 patients</article-title>. <source>J Thorac Oncol</source>.
<year>2014</year>;<volume>9</volume>:<fpage>1243</fpage>-<lpage>1248</lpage>.<pub-id pub-id-type="pmid">25122420</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-1534735420944491">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Li</surname><given-names>BT</given-names></name><name><surname>Chaft</surname><given-names>JE</given-names></name><name><surname>Kris</surname><given-names>MG.</given-names></name></person-group><article-title>Chemotherapy remains an essential element of personalized care
for persons with lung cancers</article-title>. <source>Ann Oncol</source>.
<year>2016</year>;<volume>27</volume>:<fpage>1829</fpage>-<lpage>1835</lpage>.<pub-id pub-id-type="pmid">27456296</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-1534735420944491">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonomi</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Fairclough</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>Comparison of survival and
quality of life in advanced non-small-cell lung cancer patients treated with
two dose levels of paclitaxel combined with cisplatin versus etoposide with
cisplatin: results of an Eastern Cooperative Oncology Group
trial</article-title>. <source>J Clin Oncol</source>.
<year>2000</year>;<volume>18</volume>:<fpage>623</fpage>-<lpage>631</lpage>.<pub-id pub-id-type="pmid">10653877</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-1534735420944491">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>CJ</given-names></name><name><surname>Manola</surname><given-names>J</given-names></name><name><surname>Bernardo</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal><article-title>Cisplatin-based therapy for
elderly patients with advanced non-small-cell lung cancer: implications of
Eastern Cooperative Oncology Group 5592, a randomized trial</article-title>.
<source>J Natl Cancer Inst</source>.
<year>2002</year>;<volume>94</volume>:<fpage>173</fpage>-<lpage>181</lpage>.<pub-id pub-id-type="pmid">11830607</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-1534735420944491">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>AB</given-names></name><name><surname>Nemunaitis</surname><given-names>J</given-names></name><name><surname>Denham</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal><article-title>Phase III trial of
gemcitabine plus cisplatin versus cisplatin alone in patients with locally
advanced or metastatic non-small-cell lung cancer</article-title>. <source>J
Clin Oncol</source>.
<year>2000</year>;<volume>18</volume>:<fpage>122</fpage>-<lpage>130</lpage>.<pub-id pub-id-type="pmid">10623702</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-1534735420944491">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Maestre</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal>; <collab>Spanish Lung Cancer Group</collab>.
<article-title>Preoperative chemotherapy plus surgery versus surgery plus
adjuvant chemotherapy versus surgery alone in early-stage non-small-cell
lung cancer</article-title>. <source>J Clin Oncol</source>.
<year>2010</year>;<volume>28</volume>:<fpage>3138</fpage>-<lpage>3145</lpage>.<pub-id pub-id-type="pmid">20516435</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-1534735420944491">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadpara</surname><given-names>P.</given-names></name></person-group><article-title>Determinants of early discontinuation of first-line chemotherapy,
and associated outcomes among elderly with advanced non-small cell lung
cancer</article-title>. <source>J Clin Oncol</source>.
<year>2019</year>;<volume>37</volume>(<issue>15
suppl</issue>):<fpage>9102</fpage>-<lpage>9102</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr11-1534735420944491">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maione</surname><given-names>P</given-names></name><name><surname>Perrone</surname><given-names>F</given-names></name><name><surname>Gallo</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal><article-title>Pretreatment quality of life
and functional status assessment significantly predict survival of elderly
patients with advanced non-small-cell lung cancer receiving chemotherapy: a
prognostic analysis of the multicenter Italian lung cancer in the elderly
study</article-title>. <source>J Clin Oncol</source>.
<year>2005</year>;<volume>23</volume>:<fpage>6865</fpage>-<lpage>6872</lpage>.<pub-id pub-id-type="pmid">16192578</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-1534735420944491">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movsas</surname><given-names>B</given-names></name><name><surname>Moughan</surname><given-names>J</given-names></name><name><surname>Sarna</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>Quality of life supersedes
the classic prognosticators for long-term survival in locally advanced
non-small-cell lung cancer: an analysis of RTOG 9801</article-title>.
<source>J Clin Oncol</source>.
<year>2009</year>;<volume>27</volume>:<fpage>5816</fpage>-<lpage>5822</lpage>.<pub-id pub-id-type="pmid">19858383</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-1534735420944491">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirl</surname><given-names>WF</given-names></name><name><surname>Temel</surname><given-names>JS</given-names></name><name><surname>Billings</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Depression after diagnosis
of advanced non-small cell lung cancer and survival: a pilot
study</article-title>. <source>Psychosomatics</source>.
<year>2008</year>;<volume>49</volume>:<fpage>218</fpage>-<lpage>224</lpage>.<pub-id pub-id-type="pmid">18448776</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-1534735420944491">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherif</surname><given-names>HBS</given-names></name><name><surname>Habibech</surname><given-names>S</given-names></name><name><surname>Racil</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal><article-title>Chemotherapy toxicity in
advanced non-small cell lung cancer and its impact on
survival</article-title>. <source>Eur Respir J</source>.
<year>2016</year>;<volume>48</volume>(<issue>60</issue>):<fpage>PA4841</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr15-1534735420944491">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>YN</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Mao</surname><given-names>JJ.</given-names></name></person-group><article-title>Practical application of “About Herbs” website: herbs and dietary
supplement use in oncology settings</article-title>. <source>Cancer
J</source>.
<year>2019</year>;<volume>25</volume>:<fpage>357</fpage>-<lpage>366</lpage>.<pub-id pub-id-type="pmid">31567464</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-1534735420944491">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>CJ</given-names></name><name><surname>Yen</surname><given-names>GC.</given-names></name></person-group><article-title>The in vitro and in vivo experimental evidences disclose the
chemopreventive effects of <italic>Ganoderma lucidum</italic> on cancer
invasion and metastasis</article-title>. <source>Clin Exp
Metastasis</source>.
<year>2010</year>;<volume>27</volume>:<fpage>361</fpage>-<lpage>369</lpage>.<pub-id pub-id-type="pmid">20461449</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-1534735420944491">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>BS</given-names></name><name><surname>Gao</surname><given-names>JJ</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Hattori</surname><given-names>M.</given-names></name></person-group><article-title>Triterpenes from the spores of <italic>Ganoderma lucidum</italic>
and their cytotoxicity against meth-A and LLC tumor cells</article-title>.
<source>Chem Pharm Bull</source>.
<year>2000</year>;<volume>48</volume>:<fpage>1026</fpage>-<lpage>1033</lpage>.<pub-id pub-id-type="pmid">10923835</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-1534735420944491">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>JW</given-names></name><name><surname>Zhao</surname><given-names>WM</given-names></name><name><surname>Wei</surname><given-names>DZ</given-names></name><name><surname>Zhong</surname><given-names>JJ.</given-names></name></person-group><article-title>Ganoderic acid T from <italic>Ganoderma lucidum</italic> mycelia
induces mitochondria mediated apoptosis in lung cancer
cells</article-title>. <source>Life Sci</source>.
<year>2006</year>;<volume>80</volume>:<fpage>205</fpage>-<lpage>211</lpage>.<pub-id pub-id-type="pmid">17007887</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-1534735420944491">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>QZ</given-names></name><name><surname>Lin</surname><given-names>ZB.</given-names></name></person-group><article-title><italic>Ganoderma lucidum</italic> polysaccharides peptide
inhibits the growth of vascular endothelial cell and the induction of VEGF
in human lung cancer cell</article-title>. <source>Life Sci</source>.
<year>2006</year>;<volume>78</volume>:<fpage>1457</fpage>-<lpage>1463</lpage>.<pub-id pub-id-type="pmid">16269156</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-1534735420944491">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>TK.</given-names></name></person-group><article-title>Update from Asia. Asian studies on cancer
chemoprevention</article-title>. <source>Ann N Y Acad Sci</source>.
<year>1999</year>;<volume>889</volume>:<fpage>157</fpage>-<lpage>192</lpage>.<pub-id pub-id-type="pmid">10668493</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-1534735420944491">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furusawa</surname><given-names>E</given-names></name><name><surname>Chou</surname><given-names>SC</given-names></name><name><surname>Furusawa</surname><given-names>S</given-names></name><name><surname>Hirazumi</surname><given-names>A</given-names></name><name><surname>Dang</surname><given-names>A.</given-names></name></person-group><article-title>Antitumour activity of <italic>Ganoderma lucidum</italic>, an
edible mushroom, on intraperitoneally implanted Lewis lung carcinoma in
synergenic mice</article-title>. <source>Phytother Res</source>.
<year>1992</year>;<volume>6</volume>:<fpage>300</fpage>-<lpage>304</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr22-1534735420944491">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Hsu</surname><given-names>ML</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name></person-group>, <etal>et al</etal><article-title>The anti-tumor effect of
<italic>Ganoderma lucidum</italic> is mediated by cytokines released
from activated macrophages and T lymphocytes</article-title>. <source>Int J
Cancer</source>.
<year>1997</year>;<volume>70</volume>:<fpage>699</fpage>-<lpage>705</lpage>.<pub-id pub-id-type="pmid">9096652</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-1534735420944491">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XL</given-names></name><name><surname>Lin</surname><given-names>ZB.</given-names></name></person-group><article-title>Modulation of cytokines production, granzyme B and perforin in
murine CIK cells by <italic>Ganoderma lucidum</italic>
polysaccharides</article-title>. <source>Carbohydr Polym</source>.
<year>2006</year>;<volume>63</volume>:<fpage>188</fpage>-<lpage>197</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr24-1534735420944491">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>K.</given-names></name></person-group><article-title>Antitumor and antimetastatic effects on liver of triterpenoid
fractions of <italic>Ganoderma lucidum</italic>: mechanism of action and
isolation of an active substance</article-title>. <source>Anticancer
Res</source>.
<year>2002</year>;<volume>22</volume>(<issue>6A</issue>):<fpage>3309</fpage>-<lpage>3318</lpage>.<pub-id pub-id-type="pmid">12530080</pub-id></mixed-citation>
              </ref>
              <ref id="bibr25-1534735420944491">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Wei</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>KY.</given-names></name></person-group><article-title>Antitumor effects of <italic>Ganoderma
lucidum</italic></article-title>. <source>J Chin Med</source>.
<year>1995</year>;<volume>6</volume>:<fpage>1</fpage>-<lpage>12</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr26-1534735420944491">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CZ</given-names></name><name><surname>Basila</surname><given-names>D</given-names></name><name><surname>Aung</surname><given-names>HH</given-names></name></person-group>, <etal>et al</etal><article-title>Effects of <italic>Ganoderma
lucidum</italic> extract on chemotherapy-induced nausea and vomiting in
a rat model</article-title>. <source>Am J Chin Med</source>.
<year>2005</year>;<volume>33</volume>:<fpage>807</fpage>-<lpage>815</lpage>.<pub-id pub-id-type="pmid">16265993</pub-id></mixed-citation>
              </ref>
              <ref id="bibr27-1534735420944491">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>MZ</given-names></name><name><surname>Lin</surname><given-names>LZ</given-names></name><name><surname>Lv</surname><given-names>WJ</given-names></name></person-group>, <etal>et al</etal><article-title>Effects of the
polysaccharides extracted from <italic>Ganoderma lucidum</italic> on
chemotherapy-related fatigue in mice</article-title>. <source>Int J Biol
Macromol</source>.
<year>2016</year>;<volume>91</volume>:<fpage>905</fpage>-<lpage>910</lpage>.<pub-id pub-id-type="pmid">27208798</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-1534735420944491">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>TG</given-names></name><name><surname>John</surname><given-names>M</given-names></name><name><surname>Sara Thomas</surname><given-names>G.</given-names></name></person-group><article-title>Prevention of cisplatin induced nephrotoxicity by terpenes
isolated from <italic>Ganoderma lucidum</italic> occurring in southern parts
of India</article-title>. <source>Exp Toxicol Pathol</source>.
<year>2011</year>;<volume>63</volume>:<fpage>157</fpage>-<lpage>160</lpage>.<pub-id pub-id-type="pmid">19962283</pub-id></mixed-citation>
              </ref>
              <ref id="bibr29-1534735420944491">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>WC</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Bian</surname><given-names>Z.</given-names></name></person-group><article-title>Coriolus versicolor and <italic>Ganoderma lucidum</italic>
related natural products as an adjunct therapy for cancers: a systematic
review and meta-analysis of randomized controlled trials</article-title>.
<source>Front Pharmacol</source>.
<year>2019</year>;<volume>10</volume>:<fpage>703</fpage>.<pub-id pub-id-type="pmid">31333449</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-1534735420944491">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Ruiz Beguerie</surname><given-names>J</given-names></name><name><surname>Sze</surname><given-names>DM</given-names></name><name><surname>Chan</surname><given-names>GC.</given-names></name></person-group><article-title><italic>Ganoderma lucidum</italic> (Reishi mushroom) for cancer
treatment</article-title>. <source>Cochrane Database Syst Rev</source>.
<year>2016</year>;(<issue>4</issue>):<fpage>CD007731</fpage>.<pub-id pub-id-type="pmid">27045603</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-1534735420944491">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>X.</given-names></name></person-group><article-title>Spore powder of <italic>Ganoderma lucidum</italic> improves
cancer-related fatigue in breast cancer patients undergoing endocrine
therapy: a pilot clinical trial</article-title>. <source>Evid Based
Complement Alternat Med</source>.
<year>2012</year>;<volume>2012</volume>:<fpage>809614</fpage>.<pub-id pub-id-type="pmid">22203880</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-1534735420944491">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>PP</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Ginseng and
<italic>Ganoderma lucidum</italic> use after breast cancer diagnosis and
quality of life: a report from the Shanghai Breast Cancer Survival
Study</article-title>. <source>PLoS One</source>.
<year>2012</year>;<volume>7</volume>:<fpage>e39343</fpage>.<pub-id pub-id-type="pmid">22745737</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-1534735420944491">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>X.</given-names></name></person-group><article-title>Effects of ganopoly (a <italic>Ganoderma lucidum</italic>
polysaccharide extract) on the immune functions in advanced-stage cancer
patients</article-title>. <source>Immunol Invest</source>.
<year>2003</year>;<volume>32</volume>:<fpage>201</fpage>-<lpage>215</lpage>.<pub-id pub-id-type="pmid">12916709</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-1534735420944491">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Hersh</surname><given-names>EM</given-names></name><name><surname>Talpaz</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Immune restoration and/or
augmentation of local graft versus host reaction by traditional Chinese
medicinal herbs</article-title>. <source>Cancer</source>.
<year>1983</year>;<volume>52</volume>:<fpage>70</fpage>-<lpage>73</lpage>.<pub-id pub-id-type="pmid">6336578</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-1534735420944491">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>In vitro immunomodulatory effects of an oleanolic acid-enriched
extract of <italic>Ligustrum lucidum</italic> fruit (<italic>Ligustrum
lucidum</italic> supercritical CO<sub>2</sub> extract) on piglet
immunocytes</article-title>. <source>Int Immunopharmacol</source>.
<year>2012</year>;<volume>14</volume>:<fpage>758</fpage>-<lpage>763</lpage>.<pub-id pub-id-type="pmid">23099145</pub-id></mixed-citation>
              </ref>
              <ref id="bibr36-1534735420944491">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittenhouse</surname><given-names>JR</given-names></name><name><surname>Lui</surname><given-names>PD</given-names></name><name><surname>Lau</surname><given-names>BH.</given-names></name></person-group><article-title>Chinese medicinal herbs reverse macrophage suppression induced by
urological tumors</article-title>. <source>J Urol</source>.
<year>1991</year>;<volume>146</volume>:<fpage>486</fpage>-<lpage>490</lpage>.<pub-id pub-id-type="pmid">1856958</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-1534735420944491">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>BH</given-names></name><name><surname>Ruckle</surname><given-names>HC</given-names></name><name><surname>Botolazzo</surname><given-names>T</given-names></name><name><surname>Lui</surname><given-names>PD.</given-names></name></person-group><article-title>Chinese medicinal herbs inhibit growth of murine renal cell
carcinoma</article-title>. <source>Cancer Biother</source>.
<year>1994</year>;<volume>9</volume>:<fpage>153</fpage>-<lpage>161</lpage>.<pub-id pub-id-type="pmid">7812364</pub-id></mixed-citation>
              </ref>
              <ref id="bibr38-1534735420944491">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>TC</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Effects of herbal
preparation Equiguard on hormone-responsive and hormone-refractory prostate
carcinoma cells: mechanistic studies</article-title>. <source>Int J
Oncol</source>.
<year>2002</year>;<volume>20</volume>:<fpage>681</fpage>-<lpage>689</lpage>.<pub-id pub-id-type="pmid">11894110</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-1534735420944491">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>KM</given-names></name><name><surname>He</surname><given-names>ZD</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Fung</surname><given-names>KP</given-names></name><name><surname>But</surname><given-names>PP.</given-names></name></person-group><article-title>Anti-oxidative, anti-inflammatory and hepato-protective effects
of <italic>Ligustrum robustum</italic></article-title>. <source>J
Ethnopharmacol</source>.
<year>2002</year>;<volume>83</volume>:<fpage>63</fpage>-<lpage>71</lpage>.<pub-id pub-id-type="pmid">12413708</pub-id></mixed-citation>
              </ref>
              <ref id="bibr40-1534735420944491">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yim</surname><given-names>TK</given-names></name><name><surname>Wu</surname><given-names>WK</given-names></name><name><surname>Pak</surname><given-names>WF</given-names></name><name><surname>Ko</surname><given-names>KM.</given-names></name></person-group><article-title>Hepatoprotective action of an oleanolic acid-enriched extract of
<italic>Ligustrum lucidum</italic> fruits is mediated through an
enhancement on hepatic glutathione regeneration capacity in
mice</article-title>. <source>Phytother Res</source>.
<year>2001</year>;<volume>15</volume>:<fpage>589</fpage>-<lpage>592</lpage>.<pub-id pub-id-type="pmid">11746839</pub-id></mixed-citation>
              </ref>
              <ref id="bibr41-1534735420944491">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Chang</surname><given-names>VT</given-names></name></person-group>, <etal>et al</etal><article-title>The symptom burden of
cancer: Evidence for a core set of cancer-related and treatment-related
symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and
Practice Patterns study</article-title>. <source>Cancer</source>.
<year>2013</year>;<volume>119</volume>:<fpage>4333</fpage>-<lpage>4340</lpage>.<pub-id pub-id-type="pmid">24114037</pub-id></mixed-citation>
              </ref>
              <ref id="bibr42-1534735420944491">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>TR</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal><article-title>Measuring the symptom burden
of lung cancer: the validity and utility of the lung cancer module of the
M.D. Anderson Symptom Inventory</article-title>.
<source>Oncologist</source>.
<year>2011</year>;<volume>16</volume>:<fpage>217</fpage>-<lpage>227</lpage>.<pub-id pub-id-type="pmid">21285393</pub-id></mixed-citation>
              </ref>
              <ref id="bibr43-1534735420944491">
                <label>43</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H.</given-names></name></person-group><source>Clinical Practice Guidelines of Chinese Medicine in Oncology</source>.
<publisher-name>People’s Medical Publishing House</publisher-name>;
<year>2016</year>.</mixed-citation>
              </ref>
              <ref id="bibr44-1534735420944491">
                <label>44</label>
                <mixed-citation publication-type="book"><collab>Committee of the Ministry of Health of the Republic</collab>.
<source>State Pharmacopoeia Commission of the People’s Republic of
China</source>. <publisher-name>Chemical Industry Press</publisher-name>;
<year>2000</year>.</mixed-citation>
              </ref>
              <ref id="bibr45-1534735420944491">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>DF</given-names></name><name><surname>Bonomi</surname><given-names>AE</given-names></name><name><surname>Lloyd</surname><given-names>SR</given-names></name><name><surname>Tulsky</surname><given-names>DS</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Bonomi</surname><given-names>P.</given-names></name></person-group><article-title>Reliability and validity of the Functional Assessment of Cancer
Therapy-Lung (FACT-L) quality of life instrument</article-title>.
<source>Lung Cancer</source>.
<year>1995</year>;<volume>12</volume>:<fpage>199</fpage>-<lpage>220</lpage>.<pub-id pub-id-type="pmid">7655830</pub-id></mixed-citation>
              </ref>
              <ref id="bibr46-1534735420944491">
                <label>46</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D.</given-names></name></person-group><source>Manual of the Functional Assessment of Chronic Illness Therapy (FACIT)
measurement system, Version 4</source>. <publisher-name>Center on Outcomes,
Research and Education (CORE), Evanston Northwestern Healthcare and
Northwestern University</publisher-name>;
<year>1997</year>.</mixed-citation>
              </ref>
              <ref id="bibr47-1534735420944491">
                <label>47</label>
                <mixed-citation publication-type="gov"><collab>US Department of Health and Human Services; National Institute of
Health; National Cancer Institute</collab>. <article-title>Common
terminology criteria for adverse events (CTCAE) version 4.0</article-title>.
Published May 28, 2009. <comment>Accessed July 8, 2020</comment><ext-link ext-link-type="uri" xlink:href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="bibr48-1534735420944491">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D.</given-names></name></person-group><article-title>The Functional Assessment of Cancer Therapy-Lung and Lung Cancer
Subscale assess quality of life and meaningful symptom improvement in lung
cancer</article-title>. <source>Semin Oncol</source>.
<year>2004</year>;<volume>31</volume>(<issue>3</issue><supplement>suppl
9</supplement>):<fpage>11</fpage>-<lpage>15</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr49-1534735420944491">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Fairclough</surname><given-names>DL</given-names></name></person-group>, <etal>et al</etal><article-title>What is a clinically
meaningful change on the Functional Assessment of Cancer Therapy-Lung
(FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group
(ECOG) Study 5592</article-title>. <source>J Clin Epidemiol</source>.
<year>2002</year>;<volume>55</volume>:<fpage>285</fpage>-<lpage>295</lpage>.<pub-id pub-id-type="pmid">11864800</pub-id></mixed-citation>
              </ref>
              <ref id="bibr50-1534735420944491">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name></person-group><article-title>Evaluation of traditional Chinese medicine herbs in oncology
clinical trials</article-title>. <source>Cancer J</source>.
<year>2019</year>;<volume>25</volume>:<fpage>367</fpage>-<lpage>371</lpage>.<pub-id pub-id-type="pmid">31567465</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
